Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 276

1.

The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.

Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard JP, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD.

HIV Med. 2017 Aug 31. doi: 10.1111/hiv.12546. [Epub ahead of print]

PMID:
28857427
2.

Incorporation of Rubber Powder as Filler in a New Dry-Hybrid Technology: Rheological and 3D DEM Mastic Performances Evaluation.

Vignali V, Mazzotta F, Sangiorgi C, Simone A, Lantieri C, Dondi G.

Materials (Basel). 2016 Oct 18;9(10). pii: E842. doi: 10.3390/ma9100842.

3.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016.

Antinori A, Di Biagio A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group.

New Microbiol. 2017 Apr;40(2):86-98.

4.

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group.

Infection. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5.

PMID:
28477212
5.

High Expression of Antiviral and Vitamin D Pathway Genes Are a Natural Characteristic of a Small Cohort of HIV-1-Exposed Seronegative Individuals.

Aguilar-Jimenez W, Saulle I, Trabattoni D, Vichi F, Lo Caputo S, Mazzotta F, Rugeles MT, Clerici M, Biasin M.

Front Immunol. 2017 Feb 13;8:136. doi: 10.3389/fimmu.2017.00136. eCollection 2017.

6.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.

Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group.

Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4. doi: 10.1016/j.cmi.2016.12.003. Epub 2016 Dec 9.

PMID:
27956268
7.

A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection.

Biasin M, Sironi M, Saulle I, Pontremoli C, Garziano M, Cagliani R, Trabattoni D, Lo Caputo S, Vichi F, Mazzotta F, Forni D, Riva S, Aguilar-Jimenez W, Cedeño S, Sanchez J, Brander C, Zapata W, Rugeles MT, Clerici M.

Microbes Infect. 2017 Jan;19(1):69-74. doi: 10.1016/j.micinf.2016.09.005. Epub 2016 Sep 18.

PMID:
27652980
8.

Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.

Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group.

J Antimicrob Chemother. 2016 Sep;71(9):2663-9. doi: 10.1093/jac/dkw185. Epub 2016 Jun 5.

PMID:
27272727
9.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015.

Antinori A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Di Biagio A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group.

New Microbiol. 2016 Apr;39(2):93-109. No abstract available.

10.

Identification of a Specific miRNA Profile in HIV-Exposed Seronegative Individuals.

Yahyaei S, Biasin M, Saulle I, Gnudi F, De Luca M, Tasca KI, Trabattoni D, Lo Caputo S, Mazzotta F, Clerici M.

J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):11-9. doi: 10.1097/QAI.0000000000001070.

PMID:
27171739
11.

Acute Hepatitis B After the Implementation of Universal Vaccination in Italy: Results From 22 Years of Surveillance (1993-2014).

Tosti ME, Alfonsi V, Lacorte E, Mele A, Galli C, Zanetti AR, Romanò L; SEIEVA Collaborating Group.

Clin Infect Dis. 2016 Jun 1;62(11):1412-8. doi: 10.1093/cid/ciw162. Epub 2016 Mar 23.

PMID:
27009250
12.

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.

Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Borderi M, Gibellini D, Caramatti G, Lazzarin A, Castagna A; MODAt Study Group.

J Antimicrob Chemother. 2016 Jun;71(6):1637-42. doi: 10.1093/jac/dkw031. Epub 2016 Mar 5.

PMID:
26945711
13.

Infection-related and -unrelated malignancies, HIV and the aging population.

Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J, Karpov I, Kirk O, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD.

HIV Med. 2016 Sep;17(8):590-600. doi: 10.1111/hiv.12359. Epub 2016 Feb 18.

PMID:
26890156
14.

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.

Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Castagna A, Antinori A, dʼArminio Monforte A; ICONA Foundation Study Group.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):263-71. doi: 10.1097/QAI.0000000000000849.

15.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
16.

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.

Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group.

J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24.

PMID:
26702926
17.

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.

Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group.

PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015.

18.

Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.

Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L; NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group.

HIV Med. 2016 Jun;17(6):471-8. doi: 10.1111/hiv.12344. Epub 2015 Nov 26.

PMID:
26611175
19.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators.

N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.

20.

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators.

N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16.

Supplemental Content

Loading ...
Support Center